Latest Insider Transactions at Arvinas, Inc. (ARVN)
This section provides a real-time view of insider transactions for Arvinas, Inc. (ARVN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ARVINAS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ARVINAS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 15
2023
|
Sunil Agarwal Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,242
+50.0%
|
-
|
|
Jun 15
2023
|
Linda Bain Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,121
+50.0%
|
-
|
|
Jun 15
2023
|
Everett Cunningham Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,121
+50.0%
|
-
|
|
Jun 15
2023
|
Wendy L Dixon Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,121
+31.12%
|
-
|
|
Jun 15
2023
|
Edward Moore Kennedy Jr. Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,121
+19.05%
|
-
|
|
Jun 15
2023
|
Briggs Morrison Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,121
+14.6%
|
-
|
|
Jun 15
2023
|
Leslie V Norwalk Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,121
+50.0%
|
-
|
|
Jun 15
2023
|
Alsup Laurie Smaldone Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,121
+50.0%
|
-
|
|
Jun 15
2023
|
John D Young Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,121
+50.0%
|
-
|
|
Mar 01
2023
|
John G Houston President and CEO |
SELL
Open market or private sale
|
Direct |
5,878
-0.64%
|
$170,462
$29.53 P/Share
|
|
Mar 01
2023
|
John G Houston President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
17,510
+1.86%
|
-
|
|
Mar 01
2023
|
Ian Taylor President, R&D |
SELL
Open market or private sale
|
Direct |
1,051
-1.02%
|
$30,479
$29.53 P/Share
|
|
Mar 01
2023
|
Ian Taylor President, R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
2,685
+2.55%
|
-
|
|
Mar 01
2023
|
Sean A Cassidy Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,745
-0.94%
|
$50,605
$29.53 P/Share
|
|
Mar 01
2023
|
Sean A Cassidy Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,791
+2.52%
|
-
|
|
Feb 22
2023
|
Ian Taylor President, R&D |
BUY
Grant, award, or other acquisition
|
Direct |
19,125
+16.04%
|
-
|
|
Feb 22
2023
|
John G Houston President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
61,975
+6.4%
|
-
|
|
Feb 22
2023
|
Ronald Peck Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,125
+41.21%
|
-
|
|
Feb 22
2023
|
Sean A Cassidy Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,125
+9.58%
|
-
|
|
Aug 12
2022
|
Ronald Peck Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,258
-13.37%
|
$85,544
$68.99 P/Share
|
|
Aug 12
2022
|
Ronald Peck Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,010
+29.88%
|
-
|
|
Apr 14
2022
|
Briggs Morrison Director |
SELL
Open market or private sale
|
Direct |
20,960
-20.45%
|
$1,383,360
$66.11 P/Share
|
|
Apr 14
2022
|
Briggs Morrison Director |
BUY
Exercise of conversion of derivative security
|
Direct |
16,188
+28.34%
|
$259,008
$16.0 P/Share
|
|
Mar 31
2022
|
Ian Taylor President, R&D |
SELL
Bona fide gift
|
Direct |
3,000
-3.57%
|
-
|
|
Mar 11
2022
|
Sean A Cassidy Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
15,000
-8.5%
|
$1,050,000
$70.0 P/Share
|
|
Mar 11
2022
|
Sean A Cassidy Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+7.84%
|
$240,000
$16.0 P/Share
|
|
Mar 04
2022
|
John G Houston President and CEO |
SELL
Open market or private sale
|
Direct |
6,024
-0.71%
|
$379,512
$63.94 P/Share
|
|
Mar 04
2022
|
John G Houston President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
17,511
+2.02%
|
-
|
|
Mar 04
2022
|
Sean A Cassidy Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,593
-0.98%
|
$100,359
$63.94 P/Share
|
|
Mar 04
2022
|
Sean A Cassidy Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,791
+2.85%
|
-
|
|
Mar 04
2022
|
Ian Taylor President, R&D |
SELL
Open market or private sale
|
Direct |
869
-1.02%
|
$54,747
$63.94 P/Share
|
|
Mar 04
2022
|
Ian Taylor President, R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
2,686
+3.07%
|
-
|
|
Mar 01
2022
|
Ian Taylor President, R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
3,500
+4.09%
|
$56,000
$16.0 P/Share
|
|
Feb 15
2022
|
Ian Taylor President, R&D |
SELL
Open market or private sale
|
Direct |
20,000
-3.67%
|
$1,480,000
$74.17 P/Share
|
|
Feb 15
2022
|
Ian Taylor President, R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+16.86%
|
$380,000
$19.36 P/Share
|
|
Jan 14
2022
|
Briggs Morrison Director |
SELL
Open market or private sale
|
Direct |
20,960
-14.05%
|
$1,383,360
$66.14 P/Share
|
|
Jan 14
2022
|
Briggs Morrison Director |
BUY
Exercise of conversion of derivative security
|
Direct |
16,188
+26.15%
|
$259,008
$16.0 P/Share
|
|
Dec 30
2021
|
Ronald Peck Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
20,000
-53.13%
|
$1,600,000
$80.65 P/Share
|
|
Dec 30
2021
|
Ronald Peck Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+30.11%
|
$720,000
$36.98 P/Share
|
|
Dec 17
2021
|
Sean A Cassidy Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
15,000
-8.66%
|
$1,050,000
$70.0 P/Share
|
|
Dec 17
2021
|
Sean A Cassidy Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+7.97%
|
$240,000
$16.0 P/Share
|
|
Dec 16
2021
|
Liam Ratcliffe Director |
SELL
Open market or private sale
|
Indirect |
85,705
-17.28%
|
$5,913,645
$69.32 P/Share
|
|
Dec 15
2021
|
Liam Ratcliffe Director |
SELL
Open market or private sale
|
Indirect |
113,536
-10.71%
|
$7,493,376
$66.57 P/Share
|
|
Dec 14
2021
|
Liam Ratcliffe Director |
SELL
Open market or private sale
|
Indirect |
156,464
-10.28%
|
$10,170,160
$65.2 P/Share
|
|
Nov 15
2021
|
Ian Taylor President, R&D |
SELL
Open market or private sale
|
Direct |
20,000
-7.27%
|
$1,680,000
$84.05 P/Share
|
|
Nov 15
2021
|
Ian Taylor President, R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+9.58%
|
$340,000
$17.68 P/Share
|
|
Nov 15
2021
|
Liam Ratcliffe Director |
SELL
Open market or private sale
|
Indirect |
21,284
-1.9%
|
$1,787,856
$84.49 P/Share
|
|
Nov 12
2021
|
Liam Ratcliffe Director |
SELL
Open market or private sale
|
Indirect |
39,869
-2.25%
|
$3,348,996
$84.76 P/Share
|
|
Nov 11
2021
|
Liam Ratcliffe Director |
SELL
Open market or private sale
|
Indirect |
59,799
-3.08%
|
$5,142,714
$86.67 P/Share
|
|
Nov 10
2021
|
Liam Ratcliffe Director |
SELL
Open market or private sale
|
Indirect |
13,358
-0.4%
|
$1,175,504
$88.23 P/Share
|